Clinical Trial Update: Ruxolitinib as GVHD Prophylaxis in AA Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib as prophylaxis for acute GVHD in patients undergoing HSCT for acquired aplastic anemia (AA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Aplastic Anemia
• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA | Phase 2 | Status: UNKNOWN